RT Journal Article SR Electronic T1 Vaccine strategies for prevention of community-acquired pneumonia in Canada JF Canadian Family Physician JO Can Fam Physician FD The College of Family Physicians of Canada SP 625 OP 633 DO 10.46747/cfp.6509625 VO 65 IS 9 A1 Alan Kaplan A1 Pierre Arsenault A1 Brian Aw A1 Vivien Brown A1 George Fox A1 Ron Grossman A1 Taj Jadavji A1 Craig Laferrière A1 Suzanne Levitz A1 Mark Loeb A1 Andrew McIvor A1 Christopher H. Mody A1 Yannick Poulin A1 Marla Shapiro A1 Dominique Tessier A1 Francois Théorêt A1 Karl Weiss A1 John Yaremko A1 George Zhanel YR 2019 UL http://www.cfp.ca/content/65/9/625.abstract AB Objective To describe the burden of pneumococcal disease and associated risk factors in the Canadian adult population, delineate available pneumococcal vaccines and associated efficacy and effectiveness data, and review current pneumococcal vaccine recommendations and community-acquired pneumonia (CAP) prevention strategies in Canada.Quality of evidence Pneumococcal vaccination guidelines from the Canadian National Advisory Committee on Immunization in 2013 and 2016 constitute level III evidence for CAP prevention in the Canadian adult population.Main message It is recommended that immunosuppressed adults of all ages receive the 13-valent pneumococcal conjugate vaccine (PCV13) (grades A and B recommendations). In 2016, the National Advisory Committee on Immunization also recommended that all adults aged 65 years and older receive PCV13 (grade A recommendation) on an individual basis, followed by the 23-valent pneumococcal polysaccharide vaccine (grade B recommendation). This update is based on a large clinical study that demonstrated PCV13 efficacy against vaccine-type CAP in this population.Conclusion Physicians should focus on improving pneumococcal vaccination rates among adults, which remain low. Vaccination with PCV13 should also be considered for adults with chronic conditions, whose baseline risk is often higher than that for healthy individuals aged 65 years and older.